a public good project by the
Synthesis
Company
of California

© 2026

Pancras C. Wong | doi.page

0 works0 citations0 h-index

Pancras C. Wong

Bristol-Myers Squibb (United States)(US)

Publications by Year

Research Areas

Blood Coagulation and Thrombosis Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Renin-Angiotensin System Studies, Receptor Mechanisms and Signaling, Atrial Fibrillation Management and Outcomes

Most-Cited Works

→ Angiotensin II receptors and angiotensin II receptor antagonists.(1993)1,857 cited
→ Identification of angiotensin II receptor subtypes(1989)822 cited
→ Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans(2008)601 cited
→ Nonpeptide angiotensin II receptor antagonists(1991)551 cited
→ Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa(2007)391 cited
→ Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.(1990)330 cited

→ Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.(1990)317 cited

→ Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies(2008)299 cited

→ Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).(1990)294 cited

→ Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.(1990)270 cited